ReShape Lifesciences™ Experiences Continued Momentum of Direct-to-Consumer Marketing Campaign for the Lap-Band®
New Generation of Patients are Engaged as Evidenced by Surge in Website Traffic and Doctor Referrals
Bariatric Surgeons Seeing Increases in Patient Consultations and Procedures
Insurance Coverage Continues to Improve for Bariatric Procedures
Since the beginning of the marketing campaign, in
*See disclaimer below
See our Lap-Band television ads here: https://www.reshapelifesciences.com/lapbandvideos/.
“The success at this stage of our DTC marketing campaign has led to a significant increase in potential patient and bariatric surgeon engagement, indicating that our message is clearly resonating with consumer and professional markets,” stated
Surgeon Feedback:
- “The recent interest being created by ReShape for the Lap-Band is helping me get through COVID. I am scheduling these patients as fast as possible” –
Georgia - “I have had more Lap-Band consultations in the last two months than I have had in all of 2021” –
Utah - “62% of the warm transfers have already been scheduled for consults” –
Indiana
“The above testimonials represent real-world evidence regarding the success of our marketing campaign, which should continue to promote increased demand for Lap-Band procedures and, thus, potentially a significant increase in revenues for ReShape. It is also important to note that recent market pressure has moved several insurers to reduce these mandatory wait periods and 23 states now require bariatric surgery to be included in all individual, family, and small group insurance plans, further warranting that more patients will be reimbursed for our safe, effective weight loss solution,” concluded
Throughout March, the Lap-Band is being featured in ten major publications and over 20 national cable stations. The company is also engaging in additional co-op marketing partnerships, local digital media and a national social media influencer campaign.
The Lap-Band, manufactured by
About ReShape Lifesciences™
ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the
* The National Cable TV logos used in this press release are registered trademarks of the respective stations.
1 The percentage increases for the campaign performance compares the daily average of the prelaunch baseline (January –
2 LAGB has lower risk-adjusted morbidity, readmission and reoperation/intervention rates than the LSG and LRYGB/ORYGB. Source: Hutter M., Schirmer B., Jones D., Ko C., Coher M., Merkow R., Nguyen N., First Report from
The following source describes the sleeve gastrectomy as removing 80% of the stomach: ASMBS Bariatric Surgery Procedures: Sleeve Gastrectomy: https://asmbs.org/patients/bariatric-surgery-procedures#sleeve
The following source describes how the gastric bypass uses hundreds of staples in the procedure that reduces the size of the stomach and reroutes the small intestines and digestive tract: Gastric Bypass Surgery | MedlinePlus [Online]. Available: https://medlineplus.gov/ency/article/007199.htm. [Accessed:
Forward-Looking Safe Harbor Statement:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about our expectation that the marketing campaign should continue to promote increased demand for Lap-Band procedures and, thus, potentially a significant increase in revenues for ReShape. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
CONTACTS:
Company Contact:
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com
Investor Relations Contact:
(917)-633-6086
mmiller@rxir.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/73161b8c-9a48-46ce-9314-da10c6ad2adf
Source: ReShape Lifesciences Inc